Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Glenn Michelson, MD
Sunesis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Premiere Oncology of Arizona
Scottsdale, Arizona, United States
- Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
- Duke Comprehensive Cancer Center, Duke University
Durham, North Carolina, United States
- Sarah Cannon Research Institute, Llc
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Dec 2005
- Primary completion
- 5 Mar 2007
- Completion
- 29 Nov 2007
- Last update posted
- 24 Sept 2018
- Registered enrollment
- 31
- Registry id
- NCT00252382
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.